Tabata T, Shoji T, Kikunami K, Matsushita Y, Inoue T, Tanaka S, Hino M, Miki T, Nishizawa Y, Morii H
Inoue Hospital, Osaka, Japan.
Nephron. 1988;50(4):295-8. doi: 10.1159/000185191.
The immunoregulatory effect of 1 alpha-OHD3, a precursor form of active vitamin D3 1,25 (OH)2D3, was examined in hemodialysis patients. Peripheral blood mononuclear cells (PBM) from hemodialysis patients produced significantly less interleukin-2 (IL-2) than those from normal controls. Four weeks of oral administration of 0.5 micrograms/day of 1 alpha-OHD3 enhanced the IL-2 production of PBM from the patients. This fact suggests that 1 alpha-OHD3 therapy may be useful for the restoration of IL-2 production in hemodialysis patients, and that the vitamin D3 deficiency may be responsible for the impairment of cellular immunity associated with IL-2 production disorder in hemodialysis patients.
在血液透析患者中研究了活性维生素D3 1,25(OH)2D3的前体形式1α-OHD3的免疫调节作用。血液透析患者的外周血单个核细胞（PBM）产生的白细胞介素-2（IL-2）明显少于正常对照者。每天口服0.5微克1α-OHD3，持续四周，可增强患者PBM的IL-2产生。这一事实表明，1α-OHD3治疗可能有助于恢复血液透析患者的IL-2产生，并且维生素D3缺乏可能是导致血液透析患者与IL-2产生紊乱相关的细胞免疫受损的原因。
